Green Lumber Holdings recalled its Natural Fuel For Men capsules on August 28, 2025. The FDA found the capsules contain tadalafil, a prescription ingredient not approved for this product. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Marketed without an Approved NDA/ANDA: FDA analysis found this product to contain tadalafil
Consumers and healthcare providers should stop using this product immediately. Contact Green Lumber Holdings, LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Green Lumber Natural Fuel For Men capsules are packaged in blister packs of 2, 4, 10, and 30-count. The affected model is LOT308EXP03/28. The product distributed nationwide.
The capsules contain tadalafil, which is a prescription drug used for erectile dysfunction. This poses a significant health risk as it can cause serious side effects, especially for individuals with certain medical conditions.
No specific incidents, injuries, or deaths have been reported related to this recall. However, the presence of tadalafil in an unapproved product is a serious safety concern.
Stop using the capsules immediately. Contact Green Lumber Holdings, LLC or your healthcare provider for further guidance on the recall.
For more information, consumers can visit GreenLumber.com or the FDA recall notice at the provided link.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.